Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ovid Therapeutics Q3 2026 Results: Net Loss of $20.8M, Loss Widens

Ovid Therapeutics reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to a $27.1 million loss in the prior year period. The increase in loss was primarily driven by a significant rise in research and development expenses, which grew from $19.0 million to $36.8 million year-over-year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.1
Profit before tax-20.8-12.2
Net income-20.8-12.2

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: OVID. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ovid Therapeutics Inc.: key numbers

Share price
$2.40Close, Nov 16
Market cap
$453M
Shares outstanding
188.73MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ovid Therapeutics Inc.

All →
7:03 AM ET 8-K
Financial Results

Ovid Therapeutics Financial Results

Ovid Therapeutics reported third quarter 2026 financial results, ending the period with $161.4 million in cash and marketable securities. The company highlighted clinical progress for OV329 in focal epilepsy and the initiation of a Phase 1 study for OV4071, with a projected financial runway extending into 2029.

Term
Q3 2026

“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline. We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor.”

Meg Alexander, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.